Jade Biosciences, Inc. (JBIO) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 44 days, typically, give or take 10 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Fri, Nov 13, 2026before open 44 8-K
Q2 FY2026Mon, Aug 10, 2026before open 41 8-K
Q1 FY2026Thu, May 7, 2026after close 37 8-K
Q4 FY2025Fri, Mar 6, 2026before open 65 8-K
Q3 FY2025Fri, Nov 14, 2025before open 45 8-K
Q2 FY2025Wed, Aug 13, 2025after close 44 8-K
Q1 FY2025Thu, May 1, 2025after close 31 8-K
Q1 FY2024Mon, May 13, 2024after close 43 8-K

What they guided beta

Q3 FY2026 "JADE101 Phase 3 registrational trial in IgA nephropathy (EVERGREEN) expected to initiate in the fourth quarter of 2026" exhibit
Q3 FY2026 "JADE101 Phase 2 clinical trial in IgA nephropathy (JUNIPER) ongoing; interim data expected in the second quarter of 2027" exhibit
Q3 FY2026 "JADE201 Phase 1 clinical trial in rheumatoid arthritis ongoing; interim data expected in 2027" exhibit
Q3 FY2026 "JADE301 Phase 1 clinical trial in dermatomyositis expected to initiate in the fourth quarter of 2026, with interim data expected in the second half of 2027" exhibit
Q3 FY2026 "Cash, cash equivalents, and investments of $476 million as of September 30, 2026 expected to provide runway into the fourth quarter of 2028" exhibit
Q2 FY2026 "Phase 2 JADE101 clinical trial in IgA nephropathy underway; interim data expected in 2027" exhibit
Q2 FY2026 "Phase 3 JADE101 registrational trial in IgA nephropathy expected to begin in the first half of 2027" exhibit
Q2 FY2026 "Began dosing participants with rheumatoid arthritis in Phase 1 trial of JADE201; interim data expected in 2027" exhibit
Q2 FY2026 "JADE301, a potentially best-in-class, half-life–extended anti-IFN-ß for dermatomyositis, now expected to initiate a Phase 1 healthy volunteer trial in the fourth quarter of 2026, with interim data anticipated in second half of 2027" exhibit
Q2 FY2026 "Cash, cash equivalents, and investments of $461 million as of June 30, 2026 expected to provide runway into the fourth quarter of 2028" exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/JBIO
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/JBIO

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

JBIO earnings date badge

HTML

<a href="https://veritasdata.dev/company/JBIO/"><img src="https://veritasdata.dev/embed/JBIO.svg" alt="JBIO earnings date" width="240" height="56"></a>

Markdown

[![JBIO earnings date](https://veritasdata.dev/embed/JBIO.svg)](https://veritasdata.dev/company/JBIO/)

Script

<script async src="https://veritasdata.dev/embed/JBIO.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/JBIO"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.